Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevirimat

X
Drug Profile

Bevirimat

Alternative Names: Bevirimat dimeglumine; MPC-4326; PA 103001-04; PA-457

Latest Information Update: 26 Nov 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panacos Pharmaceuticals Inc; University of North Carolina
  • Developer Myrexis
  • Class Antivirals; Small molecules; Succinates; Triterpenes
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Suspended HIV-1 infections

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 08 Jun 2010 Myrexis suspends its HIV maturation program for strategic business reasons
  • 08 Jun 2010 Suspended - Phase-II for HIV-1 infections in Australia (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top